This compound, which is a potent dual inhibitor of c-MET and VEGFR-2 signalling, has been previously used in a transgenic model of pancreatic islet tumours [110] and an orthotopic model of PC in NOD SCID mice [83]. Here, MET is linked to pachyonychia congenita.